UK government officials confirmed on Sunday that the Medicines and Healthcare products Regulatory Agency (MHRA) would imminently approve the Oxford COVID-19 vaccine, adding that the announcement could come as soon as Tuesday, according to the Financial Times.
Meantime, Pascal Soriot, chief executive of AstraZeneca (LSE: AZN), which is commercializing the vaccine, AZD1222, that was developed with Oxford University, told the Sunday Times that the company has “figured out the winning formula and how to get efficacy that, after two doses, is up there with everybody else.”
He also said it will be as effective against the virus as Pfizer (NYSE: PFE)/BioNTech’s (Nasdaq: BNTX) BNT162b2 vaccine and Moderna’s (Nasdaq: MRNA) mRNA-1273.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze